The Expression of CD24 "do-not-eat-me" Signal in Cholangiocarcinoma

NCT06707025 | Active Not Recruiting

• 2 other identifiers: 0520-23-HMOIsrael ministry of health
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators found an inverse relationship between CD24 and MiR-122 levels. Then the investigators found that CD24 that goes up with MiR-122 down makes macrophages unable to engulf the tumor cells. All this in mice. the investigators are interested in confirming this result in humans. Details of the preliminary results are attached to the submission of the research documents. the investigators will compare Cholangiocarcinoma tumors with other solid tumors, including liver tissue. The need to deepen understanding the investigators will also make a comparison between cancerous tissue and "normal" tissue adjacent to the tumor.

Conditions

Cholangiocarcinoma

Keywords

CD24; Human; Liver cancer; MiR122

Outcome Measures

Primary Outcomes (1)

• the investigators will analyze ductular reaction and cancer stem cells markers including CD24, CD44

  the investigators will perform the analysis on tissue samples of cholangiocarcinoma and non tumor controls, using immunohistochemistry and RT-PCR

  All along the study, from the first recruitment to the last recruitment. average of 1 year

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with liver cancer.

You may qualify if:

• \* Donors with cholangiocarcinoma samples

You may not qualify if:

• \* Donors who do not have cholangiocarcinoma samples

Sponsors & Collaborators

• Hadassah Medical Organization: lead

Study Sites (1)

Hdassah Hospital

Jerusalem, Israel, 9112001, Israel

Location

Biospecimen

Retention: SAMPLES WITH DNA

the investigators are collecting plasma circulating free DNA. the investigators are not performing DNA sequencing. this is similar to chipSEQ.

MeSH Terms

Conditions

Cholangiocarcinoma; Liver Neoplasms

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Officials

• Tamar Hamburger

  Hadassah Hospital Hebrew University

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: November 10, 2024
• First Posted: November 27, 2024
• Study Start: November 10, 2023
• Primary Completion: November 1, 2024
• Study Completion (Estimated): October 28, 2026
• Last Updated: March 14, 2025

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
• Time Frame: January 2028 for 7 years
• Access Criteria: After publication any one.

Locations

IL (1)